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Introduction {#sec1}
============

Therapeutic antibodies blocking the coinhibitory PD-1 pathway by targeting PD-L1 (programmed death 1 ligand 1, also known as B7-H1 or CD274) or its receptor, PD-1, have caused striking regressions in several malignancies in which RAS mutations are frequent driver events, including non-small cell lung cancer (NSCLC) ([@bib24], [@bib55]) and mismatch-repair-deficient colorectal cancer ([@bib30]). PD-L1 is critical for limiting autoimmune-related damage to normal tissues in the context of chronic inflammation but is also aberrantly upregulated on cancer cells in order to evade immune destruction ([@bib40]). As anti-PD-1 pathway immunotherapies are effective in only a minority of cancer patients ([@bib55]), there is a great need for reliable biomarkers of patient response. To what degree tumor PD-L1 expression is prognostic of patient response to PD-1 pathway blockade remains contentious. Recent clinical trials of the anti-PD-1 antibody nivolumab report that tumor cell PD-L1 expression correlates with response to nivolumab in non-squamous but not the squamous subtype of NSCLC ([@bib3], [@bib5]). Notably, non-squamous NSCLC patients with *KRAS* mutations benefited from nivolumab therapy in terms of overall survival, whereas *KRAS* wild-type patients did not ([@bib3]). Response rate and progression-free survival was increased in NSCLC patients treated with pembrolizumab in cases where at least 50% of tumor cells were positive for PD-L1 ([@bib19]). In this patient cohort, *KRAS* mutant tumors were more frequently PD-L1 positive than *KRAS* wild-type tumors.

The success of immune-checkpoint blockade is dependent on the immunogenicity of the tumor ([@bib21], [@bib32], [@bib44]), so one possible confounding factor in the use of tumor PD-L1 as a biomarker for response is the uncoupling of tumor PD-L1 expression from tumor immunogenicity. It is therefore critical to understand the signaling pathways that dictate tumor cell PD-L1 expression. The inflammatory cytokine IFN-γ is the best-characterized stimulus for PD-L1 expression, but several studies suggest that cell-intrinsic oncogenic signaling can also promote PD-L1 expression in cancer cells through epidermal growth factor receptor (EGFR), the transcription factor MYC, and the kinase AKT ([@bib1], [@bib7], [@bib41]). Studies performed on melanoma ([@bib25]) and acute myeloid leukemia ([@bib2]) have indicated that MEK signaling is involved in upregulation of PD-L1 in some tumor cell lines, but the molecular basis of this regulation remains poorly defined.

Separately, genetic rearrangements in the 3′ UTR of *CD274* (encoding PD-L1) have been found in a multitude of different cancers at low frequency and are associated with massively increased expression of tumor PD-L1 ([@bib26]). These results imply that control of PD-L1 expression through the *CD274* 3′ UTR might contribute to immune escape in human cancers, although the underlying mechanisms of post-transcriptional regulation responsible for this effect are unclear.

In this report, we reveal that tumor cell PD-L1 expression can be driven by oncogenic RAS pathway activation by a mechanism involving post-transcriptional regulation of the stability of PD-L1 mRNA. This provides a direct mechanism whereby RAS signaling in tumor cells can provide protection from attack by the immune system.

Results {#sec2}
=======

Cell-Intrinsic Upregulation of PD-L1 through Oncogenic RAS Signaling {#sec2.1}
--------------------------------------------------------------------

We tested the potential role of oncogenic RAS signaling in the regulation of PD-L1 expression in human epithelial cells using ER-RAS^G12V^ fusion constructs, which allow for the induction of oncogenic RAS activity with 4-hydroxytamoxifen (4-OHT) ([@bib38]). As expected, addition of 4-OHT led to the rapid activation of oncogenic KRAS signaling through MEK and PI3K ([Figure 1](#fig1){ref-type="fig"}A) and coincided with induction of MYC mRNA and CCND1 mRNA (encoding cyclin D1) in an immortalized human pneumocyte cell line derived from type II cells ([Figure 1](#fig1){ref-type="fig"}B; [@bib27]). PD-L1 mRNA was rapidly increased following stimulation of oncogenic KRAS signaling with 4-OHT, resulting in a 6-fold induction of mRNA expression after 3 hr ([Figure 1](#fig1){ref-type="fig"}B). By way of comparison with known regulators, stimulation with IFN-γ led to increases in PD-L1 mRNA in excess of 10-fold after 3 hr and both KRAS activation and IFN-γ stimulation dramatically increased PD-L1 protein expression at the cell surface after 48 hr ([Figure 1](#fig1){ref-type="fig"}C). Oncogenic HRAS signaling was also capable of inducing PD-L1 mRNA and protein expression in the immortalized breast epithelial cell line MCF10A and the *KRAS* wild-type colon carcinoma cell line HKE-3 ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), implying that induction of PD-L1 expression by RAS is not a tissue-specific or RAS-isoform-specific phenomenon. The induction of PD-L1 protein was most striking in ER-HRAS^G12V^ MCF10A cells, perhaps reflecting the low basal expression of PD-L1. Chronic RAS activation for 4 days led to more profound increases in PD-L1 protein, whereas shorter-term activation resulted in modest inductions of PD-L1 expression ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Importantly, 4-OHT did not induce PD-L1 expression in parental cell lines lacking ER-RAS constructs ([Figure S1](#mmc1){ref-type="supplementary-material"}C).Figure 1Cell-Intrinsic Upregulation of PD-L1 through Oncogenic RAS Signaling(A) Western blotting analysis of ER-KRAS^G12V^ type II pneumocytes treated with 4-OHT in starvation medium. Phospho-ERK and phospho-AKT was measured over time to monitor RAS pathway activation. Data are representative of two independent experiments.(B) qPCR analysis of ER-KRAS^G12V^ type II pneumocytes treated with 4-OHT or IFN-γ in starvation medium. Mean ± SEM of biological duplicates (n = 2) from the experiment described in (A).(C) Representative flow cytometry histogram of PD-L1 surface protein expression in ER-KRAS^G12V^ type II pneumocytes treated in starvation medium for 48 hr. Data are representative of two independent experiments.(D) Western blotting analysis of RAS signaling following 5 hr treatment with the KRAS^G12C^ inhibitor ARS853. Phospho-ERK and phospho-AKT signal reflect RAS pathway activity. Data are representative of two independent experiments.(E) qPCR analysis following 5 hr treatment with the KRAS^G12C^ inhibitor ARS853 (10 μM). Mean ± SEM of biological duplicates (n = 2) from the experiment described in (D).(F) Flow cytometry analysis of PD-L1 surface protein expression in H358 cells treated with ARS853 (10 μM) for 48 hr. Mean ± SEM of biological triplicates.(G) Flow cytometry analysis of PD-L1 surface protein expression in ER-KRAS^G12V^ type II pneumocytes treated in starvation medium for 24 hr. Mean ± SEM of two independent experiments.(H) qPCR analysis from the experiment described in (G). Mean ± SEM of biological triplicates pooled from two independent experiments.(I) qPCR analysis of H358 cells treated for 24 hr. Mean ± SEM of two independent experiments.(J) qPCR analysis of H358 cells treated with PMA for 3 hr following a 30 min pre-treatment with DMSO or MEK inhibitor. Mean ± SD of two independent experiments.Abbreviations and quantities are as follows: MFI, mean fluorescence intensity; EtOH, ethanol vehicle; 4-OHT, 100 nM; IFN-γ, 20 ng/mL; MEK inhibitor GSK1120212, 25 nM; PI3K inhibitor GDC-0941, 500 nM; PMA, 200 nM. ^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05, n.s., not significant. Unpaired, two-tailed Student's t tests. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Direct inhibition of KRAS signaling with the KRAS^G12C^-specific inhibitor ARS853 ([@bib33], [@bib42]) in lung and colorectal cancer cell lines harboring KRAS^G12C^ mutations led to reductions in PD-L1 mRNA expression, but not in the KRAS^G12S^ A549 control lung cancer cell line ([Figures 1](#fig1){ref-type="fig"}D and 1E). Moreover, ARS853 treatment led to significant reductions in PD-L1 surface protein expression in the *KRAS* mutant lung cancer cell line H358 ([Figure 1](#fig1){ref-type="fig"}F). To dissect which downstream effectors of RAS are responsible for regulating PD-L1 expression, we used the specific inhibitors of MEK and pan type I PI3Ks, GSK1120212 (trametinib) and GDC-0941 (pictilisib), respectively ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Notably, MEK and PI3K inhibitors could block RAS-induced expression of PD-L1 protein in ER-KRAS^G12V^ type II pneumocytes, either alone or in combination ([Figure 1](#fig1){ref-type="fig"}G). MEK inhibition significantly reversed KRAS-mediated PD-L1 mRNA upregulation ([Figure 1](#fig1){ref-type="fig"}H), but PI3K inhibition only reduced PD-L1 protein expression, concordant with evidence for AKT signaling increasing PD-L1 expression predominantly through activating translation of the transcript ([@bib41]). MEK inhibition, but not PI3K inhibition, reduced PD-L1 mRNA expression in H358 ([Figure 1](#fig1){ref-type="fig"}I), H23, and H1792 lung cancer cell lines ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Downstream of MEK, inhibition of ERK1/2 with SCH772984 potently reduced PD-L1 expression in H358 and H23 cells ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Furthermore, PMA, a potent chemical activator of MEK-ERK signaling via protein kinase C stimulation, markedly and rapidly increased PD-L1 expression, an effect that was largely reversed with the inhibition of MEK ([Figures 1](#fig1){ref-type="fig"}J and [S1](#mmc1){ref-type="supplementary-material"}G). More extensive analysis of PD-L1 surface expression on multiple *KRAS* mutant lung cancer cell lines, both human and murine, revealed generally consistent PD-L1 downregulation after MEK and PI3K inhibition, suggesting that this regulatory pathway is of broad significance ([Figure S1](#mmc1){ref-type="supplementary-material"}H). Taken together, these results suggest that oncogenic RAS signaling through MEK and PI3K is sufficient to drive PD-L1 expression.

Since RAS signaling has been implicated in reducing the expression of genes involved in the presentation of antigens by MHC class I molecules ([@bib15], [@bib16]), we analyzed the expression of antigen processing and antigen presentation machinery following oncogenic RAS activation ([Figure S1](#mmc1){ref-type="supplementary-material"}I). As expected, KRAS G12V signaling led to significant decreases in expression of *TAP1*, *TAPBP*, as well as *HLA-A*, *HLA-B*, *HLA-C*, and *B2M*, suggesting that compromised antigen processing and presentation in concert with increases in PD-L1 expression may contribute to an augmented state of immunoresistance in *RAS* mutant tumor cells.

RAS Signaling Increases PD-L1 mRNA Stability through AU-Rich Elements in the 3′ UTR {#sec2.2}
-----------------------------------------------------------------------------------

To investigate how RAS-MEK signaling regulates PD-L1 expression, we first asked whether RAS regulates PD-L1 via a transcriptional mechanism. We generated a series of luciferase reporter constructs containing promoter fragments cloned from the human *CD274* locus ([Figure S2](#mmc1){ref-type="supplementary-material"}A). In all cases, the physiological stimulus IFN-γ, but not PMA, induced expression of the promoter reporter constructs in H358 cells, a cell line in which endogenous PD-L1 mRNA expression is robustly induced with PMA ([Figure 1](#fig1){ref-type="fig"}J). Incorporation of putative enhancer elements ([@bib50]) into the *CD274* promoter reporter constructs also failed to confer sensitivity to MAPK activation ([Figure S2](#mmc1){ref-type="supplementary-material"}A), as did including predicted regulatory regions spanning the 5′ of exon 1 (data not shown). Furthermore, none of the reporters showed evidence of decreased expression when H358 cells were treated with MEK inhibitor (data not shown).

Therefore, we investigated possible mechanisms of post-transcriptional regulation of PD-L1 expression by RAS. We induced oncogenic KRAS signaling with 4-OHT in ER-KRAS^G12V^ type II pneumocytes and concomitantly blocked transcription with actinomycin D. Surprisingly, we found human PD-L1 mRNA to have a short half-life, which was significantly stabilized by the induction of oncogenic KRAS signaling ([Figure 2](#fig2){ref-type="fig"}A). Moreover, murine PD-L1 mRNA also had a comparably short half-life, and the stability of the transcript in a *Kras* mutant, p53-deleted murine lung tumor cell line (KPB6), could be reduced further still when MEK was inhibited ([Figure 2](#fig2){ref-type="fig"}B), implicating KRAS-MEK signaling in the stabilization of the labile PD-L1 transcript. Consistently, direct inhibition of oncogenic KRAS signaling with ARS853 also caused reductions in PD-L1 mRNA half-life in H23, H1792, and H358 cells ([Figure 2](#fig2){ref-type="fig"}C). However, inhibition of PI3K alone did not result in altered PD-L1 mRNA stability in KPB6 cells ([Figure S2](#mmc1){ref-type="supplementary-material"}B).Figure 2RAS Signaling Increases PD-L1 mRNA Stability through AU-Rich Elements in the 3′ UTR(A) qPCR analysis of PD-L1 mRNA stability in ER-KRAS^G12V^ type II pneumocytes after the concomitant addition of actinomycin D (5 μg/mL or 10 μg/mL) and 4-OHT or vehicle added at time = 0 hr in starvation medium. Mean ± SEM of two independent experiments. ^∗∗∗^p \< 0.0005; two-way ANOVA.(B) qPCR analysis of PD-L1 mRNA stability in KPB6 cells after the addition of actinomycin D (5 μg/mL) and DMSO or MEK inhibitor. Cells were pre-treated with DMSO or MEK inhibitor for 30 min before actinomycin D addition. Mean ± SEM of two independent experiments. ^∗∗∗^p \< 0.0005; two-way ANOVA.(C) qPCR analysis of PD-L1 mRNA stability after the addition of actinomycin D (5 μg/mL) and DMSO or ARS853. Cells were pre-treated with DMSO or ARS853 for 35 min before actinomycin D addition. Mean ± SEM of two independent experiments. ^∗∗∗^p \< 0.0005; two-way ANOVA.(D) Sequence alignment of conserved AU-rich element ATTTA pentamer sequences (highlighted in red) in the mouse and human *CD274* 3′ UTR.(E) Normalized luciferase signal in ER-HRAS^G12V^ MCF10A cells from wild-type (ATTTA x 6) or mutant (ATGTA x 6) PD-L1 3′ UTR reporters, 24 hr after treatment in starvation medium. Mean ± SEM of three independent experiments.(F) Normalized luciferase signal in H358 cells from wild-type (ATTTA x 6) or mutant (ATGTA x 6) PD-L1 3′ UTR reporters, 6 hr after treatment. Mean ± SEM of three independent experiments.Abbreviations and quantities: 4-OHT, 100 nM; MEK inhibitor GSK1120212, 25 nM; PMA, 200 nM. ^∗∗∗^p \< 0.0005, ^∗∗^p \< 0.005, ^∗^p \< 0.05, n.s., not significant. Unpaired, two-tailed Student's t tests. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Common genetic elements conferring mRNA instability include miRNA binding sites and AU-rich elements (AREs) in the 3′ UTR of the transcript. The core motif for AREs is an ATTTA pentamer sequence, but functional AREs are often found in an AU-rich context, conforming to the WWATTTAWW nonamer consensus (where W denotes an A or T) ([@bib58]) constituting the binding site for several AU-rich element binding proteins (AUBPs), which can subsequently recruit mRNA decay machinery ([@bib36]). For example, a canonical ARE-regulated transcript is *TNF*, which contains nine pentamer sequences in the human transcript and eight pentamers in the murine transcript. Upon inspection of the 3′ UTR of PD-L1 mRNA, we noted a high number of ARE pentamers. Specifically, out of 14 ATTTA pentamer sequences in the human transcript and 11 in the murine transcript, there were 3 conserved AREs conforming to the nonamer consensus ([Figure 2](#fig2){ref-type="fig"}D).

We tested the influence of MEK inhibition on the half-life of another unstable transcript, Tusc2 mRNA (tumor suppressor candidate 2, or Fus1), which does not contain AU-rich elements in the 3′ UTR but is targeted by multiple miRNAs ([@bib14]). Although Tusc2 mRNA had a similar half-life to PD-L1 mRNA, MEK inhibition did not influence the stability of the Tusc2 transcript ([Figure S2](#mmc1){ref-type="supplementary-material"}C), indicating that the observed post-transcriptional regulation of PD-L1 by MEK may relate to AU-rich elements in the 3′ UTR. Indeed, a transcript containing functional AU-rich elements, Ptgs2 mRNA ([@bib8]), displayed a significant reduction in mRNA half-life in response to MEK inhibition ([Figure S2](#mmc1){ref-type="supplementary-material"}C), reminiscent of PD-L1 mRNA.

To directly analyze the functional importance of these AREs, we constructed a luciferase reporter containing a fragment of the 3′ UTR of human *CD274* containing the last six ATTTA pentamers, including the three conserved nonamer sequences. Mutation of ATTTA pentamers to ATGTA has been shown to increase the expression of ARE-containing mRNAs ([@bib43], [@bib56]). Consistent with this, mutating the six ATTTA pentamer sequences to ATGTA increased expression of the PD-L1 3′ UTR luciferase reporter in ER-HRAS^G12V^ MCF10A and H358 cells, suggesting that these AREs are functionally relevant for controlling the expression of PD-L1 ([Figures 2](#fig2){ref-type="fig"}E and 2F). Stimulation with 4-OHT in ER-HRAS^G12V^ MCF10A cells, or PMA in H358 cells, increased expression of the wild-type reporter, whereas the ATGTA mutant reporter was insensitive to these treatments ([Figures 2](#fig2){ref-type="fig"}E and 2F). In sum, these data suggest that AREs in the 3′ UTR of PD-L1 mRNA can mediate control of PD-L1 expression by RAS-MEK signaling.

AU-Rich Element Binding Proteins TTP and KSRP Are Negative Regulators of PD-L1 Expression {#sec2.3}
-----------------------------------------------------------------------------------------

To assess which AU-rich element binding proteins (AUBPs) could mediate regulation of PD-L1 expression downstream of RAS signaling, we performed a selected siRNA screen of likely candidate genes, *AUF1*, *KSRP*, *HuR*, and *TTP* (also known as tristetraprolin or *ZFP36*), in three *RAS* mutant lung cancer cell lines ([Figures 3](#fig3){ref-type="fig"}A--3C). Knockdown efficiency was verified in each case by qPCR ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). siRNA-mediated knockdown of KSRP and TTP most consistently increased PD-L1 mRNA expression across the cell line panel, with the exception of A427, where knock-down of TTP did not lead to significant increases in PD-L1 mRNA levels. Overexpression of KSRP or TTP was sufficient to significantly decrease PD-L1 expression ([Figure 3](#fig3){ref-type="fig"}D) and PD-L1 3′ UTR luciferase reporter expression in H358 cells ([Figure 3](#fig3){ref-type="fig"}E), corroborating our results from the siRNA screen and confirming that KSRP and TTP impart their negative regulation of PD-L1 expression through the 3′ UTR. Overexpression of TTP and KSRP together did not result in additive reductions in PD-L1 expression, suggesting that they may regulate PD-L1 through the same mechanism ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Notably, siRNA-mediated knockdown of TTP family members, BRF-1 and BRF-2, was incapable of increasing PD-L1 expression to the extent achieved by silencing TTP expression ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F). We confirmed that TTP protein expression was reduced following knock-down in H23 and H358 cells, but this was less clear in A427 cells, which express lower levels of TTP protein ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Deconvolution of siRNA pools targeting TTP showed that multiple siRNAs increased expression of PD-L1 mRNA in H23 and H358 cells ([Figure S3](#mmc1){ref-type="supplementary-material"}H).Figure 3AU-Rich Element Binding Proteins TTP and KSRP Are Negative Regulators of PD-L1 Expression(A--C) qPCR analysis 48 hr after transfection with siRNAs targeting AU-rich element binding proteins (AU-BPs) relative to siScrambled (siSc) control. Mean ± SD of biological triplicates.(D) qPCR and western blotting analysis of H358 cells 24 hr after transfection. qPCR data represent the mean ± SD of biological triplicates and are representative of two independent experiments. ^∗^, non-specific band.(E) Normalized luciferase signal from the wild-type, PD-L1 3′ UTR reporter 24 hr after co-transfection with the indicated constructs. Mean ± SEM of two independent experiments.(F) qPCR analysis after serum stimulation in serum-starved TTP WT or TTP KO MEFs. Mean ± SEM of two independent experiments.(G) qPCR analysis of PD-L1 mRNA stability after the addition of actinomycin D (5 μg/mL) in TTP WT or TTP KO MEFs. Mean ± SEM of two independent experiments.(H) Normalized luciferase signal in KPB6 TTP (tet-ON) cells wild-type (ATTTA x 6) or mutant (ATGTA x 6) PD-L1 3′ UTR reporters, 7 hr after treatment. Data represent the mean ± SEM of biological triplicates and are representative of two independent experiments.Abbreviations and quantities: MEK inhibitor, GSK1120212, 25 nM; Dox., doxycycline 1 μg/mL. ^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01. Unpaired, two-tailed Student's t tests. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

We further examined the regulation of PD-L1 mRNA by TTP by using TTP wild-type (WT) and TTP knock-out (KO) MEFs. In the TTP KO MEFs, TTP mRNA is expressed but no functional TTP protein can be made due to the introduction of a premature stop codon at the endogenous locus ([@bib28], [@bib54]). Acute activation of TTP expression with serum temporally coincided with a substantial and transient decrease in PD-L1 mRNA in TTP WT MEFs, but not in the TTP KO MEFs ([Figure 3](#fig3){ref-type="fig"}F), with PD-L1 levels recovering to near baseline at 6 hr after serum addition. Moreover, the total absence of functional TTP protein in the TTP KO MEFs increased the half-life of PD-L1 mRNA relative to TTP WT MEFs ([Figure 3](#fig3){ref-type="fig"}G).

Finally, we generated a KPB6 lung cancer cell line with a tetracycline-inducible TTP transgene (TTP tet-ON). As expected, inducible expression of TTP led to reductions in wild-type PD-L1 3′ UTR luciferase reporter expression, but not of the ATGTA mutant 3′ UTR reporter ([Figure 3](#fig3){ref-type="fig"}H). When combined with MEK inhibition, TTP expression more robustly suppressed expression of the wild-type reporter. In sum, these data provide evidence for the negative regulation of PD-L1 mRNA expression by the AUBPs KSRP and TTP.

RAS Regulates PD-L1 Expression through TTP {#sec2.4}
------------------------------------------

To further investigate whether MEK and TTP regulate PD-L1 via a shared pathway, we silenced TTP expression using siRNAs in the context of MEK inhibition. Knock-down of TTP was largely able to rescue the decrease in PD-L1 expression caused by MEK inhibition ([Figure 4](#fig4){ref-type="fig"}A). However, the knockdown of KSRP could not rescue this phenotype, despite profound silencing of expression ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Furthermore, MEK inhibition significantly increased TTP mRNA expression ([Figure 4](#fig4){ref-type="fig"}A), and chronic activation of oncogenic KRAS signaling significantly decreased TTP mRNA expression ([Figure 4](#fig4){ref-type="fig"}B).Figure 4RAS Regulates PD-L1 Expression through TTP(A) qPCR analysis of H358 cells following siRNA-mediated knock-down of TTP (24 hr) followed by MEK inhibition (24 hr). Mean ± SEM of two independent experiments.(B) qPCR analysis of ER-KRAS^G12V^ type II pneumocytes treated for 24 hr in starvation medium. Mean ± SEM of three independent experiments.(C) qPCR analysis of RNA-IP immunoprecipitates from H358 cells. Mean ± SEM from biological triplicates.(D) Western blotting analysis of H358 cells expressing the indicated constructs. 6.5 hr post-transfection, cells were treated with DMSO or MEK inhibitor for an additional 16 hr. Arrow indicates Myc-TTP. Data are representative of two independent experiments.(E) Western blotting analysis of immunoprecipitations from H358 cells transfected with Myc-TTP. 6.5 hr post-transfection, cells were treated with DMSO or MEK inhibitor for an additional 16 hr. Arrow indicates Myc-TTP; ^∗^ indicates co-precipitating protein. Data are representative of two independent experiments.(F) qPCR analysis of TTP WT or TTP KO MEFs treated with okadaic acid or DMSO for 2 hr. Mean ± SEM of two independent experiments.Abbreviations and quantities: EtOH, ethanol vehicle; 4-OHT, 100 nM; okadaic acid, OA, 1 μM; MEK inhibitor, GSK1120212, 25 nM. ^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01. Unpaired, two-tailed Student's t tests. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Next, we tested whether the RAS pathway regulates the activity of TTP and/or KSRP protein. Crucially, we found that endogenous levels of TTP and KSRP both co-precipitated with PD-L1 mRNA in RNA immunoprecipitation (RNA-IP) reactions from KPB6 mouse lung cancer cells ([Figure S4](#mmc1){ref-type="supplementary-material"}B). TTP also significantly bound to PD-L1 mRNA in H358 cells ([Figure 4](#fig4){ref-type="fig"}C). In all cases, the enrichment for the PD-L1 transcript was far greater than that of a control mRNA, GAPDH, which lacks AREs in the 3′ UTR ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}C). MEK inhibition did not significantly alter the occupancy of TTP or KSRP on PD-L1 mRNA, consistent with RAS regulating the activity of the AUBP, rather than the occupancy on the target mRNA.

ERK has been shown to phosphorylate ([@bib53]) and negatively regulate TTP activity and expression ([@bib4], [@bib11], [@bib17], [@bib23]). Inhibition of MEK decreased phosphorylation of TTP at PXSP (ERK target-site consensus) and RXXS/T (RSK/AKT target-site consensus) motifs ([Figures 4](#fig4){ref-type="fig"}D and 4E), confirming that TTP is regulated by phosphorylation downstream of MEK signaling in cancer cells. Mutation of two of the highest confidence predicted ERK-target residues on human TTP (S218 and S228) abrogated detection of TTP with the phospho-PXSP motif-specific antibody ([Figure 4](#fig4){ref-type="fig"}D), but the phosphosite mutant TTP (S218A 228A) did not show enhanced activity in reducing PD-L1 mRNA expression compared to wild-type TTP (data not shown), implying the involvement of other residues that are not readily detected with this antibody. Furthermore, although AKT signaling has been shown to regulate KSRP activity through phosphorylation of S193 ([@bib12]), the KSRP S193A phosphosite mutant did not show enhanced activity in reducing PD-L1 mRNA expression compared to wild-type KSRP ([Figure S4](#mmc1){ref-type="supplementary-material"}D).

Equally, the serine/threonine phosphatase PP2A has been implicated in positively regulating TTP function by reversing inhibitory phosphorylation events ([@bib51]). Therefore, we tested whether inhibition of PP2A with okadaic acid (OA) would increase PD-L1 expression. OA rapidly increased PD-L1 mRNA expression in TTP WT MEFs, but not TTP KO MEFs ([Figure 4](#fig4){ref-type="fig"}F), demonstrating that PP2A activity decreases PD-L1 expression specifically through modulating TTP activity.

RAS-ROS-p38 Signaling Controls TTP Activity {#sec2.5}
-------------------------------------------

To discover which residues are functionally important for regulating TTP activity downstream of RAS, we performed mass spectrometry on immunoprecipitated Myc-TTP after PMA, MEK inhibitor, or PMA and MEK inhibitor treatment. We used the *Kras* mutant, mouse colon carcinoma cell line CT26, based on its immunogenicity and sensitivity to anti-PD-L1 antibody therapy, making it suitable for downstream *in vivo* experiments. Most notably, mass spectrometry analysis revealed MEK-dependent phosphorylation of S52 and S178; PMA significantly enhanced phosphorylation of these residues, and this effect was reversed with MEK inhibition ([Figures 5](#fig5){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A and [Table S1](#mmc1){ref-type="supplementary-material"}). Moreover, MEK inhibition alone was sufficient to reduce phosphorylation of these residues ([Figure 5](#fig5){ref-type="fig"}A).Figure 5RAS-ROS-p38 Signaling Controls TTP Activity(A) Histograms represent peak areas from extracted ion chromatograms for non-phosphorylated and phosphorylated peptides corresponding to S52 and S178 phosphosites of mouse TTP. Myc-TTP was immunoprecipitated from CT26 Myc-TTP (tet-ON) cells 1 hr after the indicated treatment. Mean ± SD of technical triplicates. Representative of two independent biological experiments.(B) qPCR analysis of ER-KRAS^G12V^ type II pneumocytes treated in starvation medium for 24 hr. Mean ± SEM of four independent experiments.(C) Representative flow cytometry histograms of PD-L1 surface protein expression in MCF10A ER-ΔMEKK3 cells treated in starvation medium for 1 day or 4 days. Data are representative of two independent experiments.(D) Flow cytometry analysis of PD-L1 surface protein expression on ER-HRAS^G12V^ MCF10A cells (24 hr) and ER-HRAS^G12V^ HKE-3 cells (48 hr) after treatment in starvation medium. Data are representative of biological duplicates.(E) qPCR analysis of CT26 cells at 2 hr or 24 hr after MK2 inhibition with PF 3644022. Mean ± SEM of two independent experiments.(F) Sequence alignments of the conserved phosphosites (highlighted red) targeted by MK2 in mouse (*Mm*) and human (*Hs*) TTP protein.(G) Western blotting of immunoprecipitations from CT26 TTP KO cells harboring tet-ON, WT, or phospho mutant, Myc-TTP constructs. Cells were treated with dox. for 24 hr before the addition of PMA or DMSO for 1 hr. Arrow indicates Myc-TTP. Data are representative of two independent experiments.(H) qPCR analysis of CT26 TTP KO cells harboring tet-ON, WT, or phospho mutant, Myc-TTP constructs, treated with dox or vehicle for 48 hr. Data represent the mean ± SEM of two independent experiments.^∗∗^p \< 0.005, ^∗^p \< 0.05. Unpaired, two-tailed Student's t test. Abbreviations and quantities: 4-OHT, 100 nM; NAC, N-acetyl-L-cysteine, 10 mM; PMA, 200 nM; MEK inhibitor, GSK1120212, 25 nM; MK2 inhibitor PF 3644022, 1 μM; MK2 inhibitor III, 1 μM; dox., doxycycline, 1 μg/mL. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

S52 and S178 residues are crucial for the regulation of TTP activity through binding to 14-3-3 proteins following phosphorylation by MK2 (also known as MAPKAPK2) downstream of p38 ([@bib9]). Consequently, p38 signaling results in decreased TTP activity, partly through reducing the association with deadenylase machinery ([@bib37], [@bib48]). In parallel, phosphorylation of S52 and S178 stabilizes TTP protein ([@bib6]), which is consistent with the observed increase in abundance of total TTP peptides detected in the PMA versus the MEK inhibitor-treated condition ([Figure 5](#fig5){ref-type="fig"}A).

We reasoned that oncogenic RAS might stimulate p38 signaling through promoting the MEK-dependent accumulation of reactive oxygen species (ROS) ([@bib39]) and thus inhibit TTP function. Indeed, oncogenic RAS signaling dramatically increased intracellular ROS in MCF10A cells, and ROS levels were distinctly correlated with the extent of PD-L1 induction ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Furthermore, the addition of the potent anti-oxidant N-acetyl-L-cysteine (NAC) largely reversed the induction of PD-L1 protein by RAS ([Figures 5](#fig5){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}B), collectively suggesting that ROS induction by oncogenic RAS is functionally important in driving PD-L1 expression.

Specific activation of the p38 pathway using an inducible version of the upstream kinase MEKK3 (ΔMEKK3-ER) ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}C; [@bib18]) was sufficient to increase PD-L1 protein expression, albeit to a lesser extent than that achieved by RAS itself. Co-treatment with NAC was considerably less effective in reversing PD-L1 induction in this context, consistent with ROS operating upstream of p38 in this pathway ([Figure 5](#fig5){ref-type="fig"}C). Moreover, inhibition of MK2 strongly reversed RAS-induced PD-L1 expression in MCF10A and HKE-3 cells ([Figure 5](#fig5){ref-type="fig"}D) and PD-L1 expression in CT26 cells, which have endogenous levels of mutant KRAS ([Figure 5](#fig5){ref-type="fig"}E). We also observed reductions in expression of PD-L1 mRNA in several NSCLC cell lines with endogenous *KRAS* mutations following treatment with NAC, reduced glutathione, or MK2 inhibitor III ([Figure S5](#mmc1){ref-type="supplementary-material"}D), although we noted some heterogeneity in response between the four cell lines tested.

To directly test the functional significance of the MK2 target residues downstream of MEK pathway activation, we generated TTP knock-out CT26 cell lines using CRISPR/Cas (to obviate functional contributions from endogenous TTP) and reconstituted these cells with either a wild-type (WT) or phosphosite mutant (S52A S178A), tetracycline-inducible TTP transgene. S52 and S178 of mouse TTP are highly conserved, with S52 conforming to the RXXS/T phosphosite motif ([Figure 5](#fig5){ref-type="fig"}F). Immunoprecipitation of Myc-tagged TTP following acute MAPK activation with PMA revealed phosphorylation of WT TTP, but not of the S52A S178A mutant protein at RXXS/T sites ([Figure 5](#fig5){ref-type="fig"}G), verifying our findings from mass spectrometry analysis. Crucially, the S52A S178A mutant TTP had significantly enhanced activity in reducing PD-L1 mRNA expression relative to WT TTP ([Figures 5](#fig5){ref-type="fig"}H and [S5](#mmc1){ref-type="supplementary-material"}E). In sum, these results suggest that a RAS-ROS-p38 signaling axis contributes to PD-L1 upregulation through phosphorylation and inactivation of TTP.

RAS Pathway Activation Is Associated with PD-L1 Upregulation in Human Cancers {#sec2.6}
-----------------------------------------------------------------------------

To further evaluate the role of oncogenic RAS signaling in regulating PD-L1 expression in cancer, we analyzed TCGA gene expression data from patient-derived lung adenocarcinoma (LUAD) or colon adenocarcinoma (COAD) samples. To account for the effects of alternative oncogenes that can activate downstream RAS effector pathways such as EGFR, BRAF, and ALK, we used two published gene expression signatures for RAS activation ([@bib35], [@bib52]) to segregate patient samples into "high" and "low" RAS pathway activity based on gene expression. As expected, annotation of *KRAS* mutation status revealed a strong enrichment for *KRAS* mutant samples in the high RAS activity cohorts in both signatures ([Figures 6](#fig6){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}A). We compared the expression of T cell function-related genes between high and low RAS activity cohorts and found *CD274* (encoding PD-L1) expression to be significantly increased in the high RAS pathway activity samples in LUAD (1.42 log2-fold change) and COAD (1.17 log2-fold change) samples, using either signature ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S6](#mmc1){ref-type="supplementary-material"}A). Stromal PD-L1 and tumor PD-L1 expression appear to have independent, suppressive effects on anti-tumor immunity ([@bib29]), but we noted that the expression of the pan-leukocyte marker *PTPRC* (coding for CD45) and lymphocyte marker *CD3E* were only modestly increased in the high RAS pathway activity cohort, indicating that the differential in PD-L1 expression is not likely to be solely attributable to a higher degree of leukocyte infiltration in the tumor microenvironment ([Figure 6](#fig6){ref-type="fig"}A).Figure 6RAS Pathway Activation Is Associated with PD-L1 Upregulation in Human Cancers(A) Heat-maps showing fold change in expression of T cell function related genes between high and low RAS pathway activity cohorts of lung adenocarcinoma (LUAD) and colon adenocarcinoma (COAD) TCGA samples. *KRAS* mutation status (codons 12, 13, and 61) is indicated for each sample. Genes are ranked in order of significance. Wald test, DESeq2.(B) Box-and-whisker plots comparing PD-L1 mRNA expression in RAS high versus low pathway activity cohorts in LUAD and COAD using two independent RAS gene expression signatures. Wald test, DESeq2.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Of note, *IFNGR1* was also among the most significantly enriched transcripts in the high RAS pathway activity groups. To investigate the possibility that PD-L1 may be upregulated in RAS active tumors due to regulation by IFNGR1, we induced PD-L1 expression with RAS in ER-KRAS^G12V^ type II pneumocytes and concomitantly blocked IFNGR1 signaling using a depleting antibody for IFN-γ or with the JAK1/2 inhibitor ruxolitinib. Although both treatments effectively reduced responses to exogenous IFN-γ, PD-L1 induction by RAS was unaffected, suggesting independence from IFN-γ-IFNGR1 signaling ([Figure 6](#fig6){ref-type="fig"}SB).

To further explore the *in vivo* relevance of TTP regulation in human cancer, we compared TTP mRNA expression in normal tissue and tumor samples by using publically available datasets. TTP mRNA was strikingly downregulated in human lung and colon tumor samples compared to normal tissue ([Figure S6](#mmc1){ref-type="supplementary-material"}C; [@bib46], [@bib47]), confirming that aberrant regulation of TTP expression is relevant in the human disease. Consistently, in FACS-sorted epithelial cells isolated from normal lung or matched tumor tissue from *Kras*^*LSL-G12D/+*^; *Trp53*^*F/F*^ (KP) mice, TTP mRNA expression was reduced in lung tumor tissue ([Figure S6](#mmc1){ref-type="supplementary-material"}D). PD-L1 mRNA expression was generally higher in tumor tissue than in normal lung but not significantly increased; however, PD-L1 protein expression was significantly elevated, perhaps reflecting the contribution from AKT in promoting PD-L1 protein expression ([Figure S6](#mmc1){ref-type="supplementary-material"}E).

Restoration of Tumor Cell TTP Expression Enhances Anti-tumor Immunity {#sec2.7}
---------------------------------------------------------------------

Next, we set out to directly assess the functional importance of the regulation of PD-L1 expression by TTP in tumor progression. To this end, we generated a series of stable CT26 cell lines expressing Myc-tagged mouse TTP under a tetracycline-inducible promoter (TTP tet-ON), and in addition, constitutively expressing either empty vector or mouse *Cd274* cDNA lacking the 3′ UTR (PD-L1 Δ3′ UTR). TTP expression was induced upon addition of doxycycline in a dose-dependent manner ([Figure 7](#fig7){ref-type="fig"}A), resulting in decreased PD-L1 protein expression at the cell surface ([Figure 7](#fig7){ref-type="fig"}B). Overexpression of PD-L1 Δ3′ UTR rendered total PD-L1 levels effectively insensitive to TTP induction ([Figure 7](#fig7){ref-type="fig"}B). TTP transgene expression with doxycycline was also associated with a decrease in PD-L1 mRNA stability, which was comparable to that mediated by MEK inhibition in this system ([Figure S7](#mmc1){ref-type="supplementary-material"}A).Figure 7Restoration of Tumor Cell TTP Expression Enhances Anti-tumor Immunity(A) Western blotting analysis of CT26 Myc-TTP tet-ON cells expressing either empty vector or mouse *Cd274* cDNA lacking the 3′ UTR (PD-L1 Δ3′ UTR), 24 hr after treatment (Dox., 0.1 μg/mL or 1 μg/mL). Arrow indicates Myc-TTP. Data are representative of two independent experiments.(B) Representative flow cytometry histograms of PD-L1 surface protein expression in CT26 stable cells lines in (A), 72 hr after treatment (Dox., 1 μg/mL). Data are representative of three independent experiments.(C) Tumor growth curves for CT26-derived cell lines subcutaneously transplanted into BALB/c mice (n = 8 per group).(D) Tumor growth curves for MC38-derived cell lines subcutaneously transplanted into C57BL/6 mice (n = 6 per group). X denotes the loss of a doxycycline-treated mouse.(E) Tumor growth curves for CT26-derived cell lines subcutaneously transplanted into *nu/nu* mice (n = 6 per group).(F) Tumor growth curves for CT26-derived cell lines subcutaneously transplanted into BALB/c mice (n = 4--5 per group).For (C)--(F), data represent the mean ± SEM from individual experiments. ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001, n.s., not significant; two-way ANOVA.(G) Histological analysis of subcutaneous tumors at the end-point from the experiment described in (C), with quantification of CD3^+^ cells in 5 fields of view per mouse with 5--6 mice per group. Mean ± SEM. ^∗∗^p \< 0.01; unpaired, two-tailed Student's t test.(H) Quantification of CD8^+^/Treg cell ratios and CD8^+^ IFN-γ^+^ cells from flow cytometry analysis of tumors after 18--20 days of growth. Each data point represents data from an individual mouse; mean ± SEM. ^∗^p \< 0.05; unpaired, two-tailed Student's t test. Data are pooled from two independent experiments.(I) Proposed molecular model. Signaling nodes that influence anti-tumor immunity and are amenable to inhibition with drugs used in this study are highlighted. S52 and S178 represent MK2 target sites and numbering corresponds to mouse TTP. OA, okadaic acid.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

To independently verify our findings in another cell line, we used MC38 tumor cells because they are known to exhibit sensitivity to PD-L1 modulation *in vivo* and show RAS pathway activation ([@bib20]). As expected, TTP was induced with doxycycline in MC38 (tet-ON) cells, leading to reductions in PD-L1 expression ([Figures S7](#mmc1){ref-type="supplementary-material"}B and S7C).

Using these engineered cell lines, we performed subcutaneous transplantation experiments in mice and monitored tumor progression. Notably, the growth rates of the stable cell lines *in vitro* did not significantly differ with the overexpression of PD-L1 Δ3′ UTR cDNA or the induction of TTP transgene expression with doxycycline ([Figure S7](#mmc1){ref-type="supplementary-material"}D and S7E). However, *in vivo*, doxycycline treatment significantly reduced CT26 and MC38 tumor growth in immune-competent, syngeneic mice ([Figures 7](#fig7){ref-type="fig"}C and 7D). Strikingly, the anti-tumor effects mediated by doxycycline treatment were absent in immunocompromised *nu/nu* mice harboring CT26 tumors ([Figure 7](#fig7){ref-type="fig"}E) and in mice treated with depleting antibodies against CD8 and CD4, implying an essential contribution from the adaptive immune system to this anti-tumor response ([Figure 7](#fig7){ref-type="fig"}F). CT26 tumor cells overexpressing PD-L1 Δ3′ UTR grew faster than the empty vector cells in BALB/c mice but had no growth advantage in *nu/nu* mice. Moreover, expression of PD-L1 Δ3′ UTR was able to rescue much of the growth inhibition mediated by doxycycline treatment in BALB/c mice, suggesting that suppression of tumor cell PD-L1 expression is an essential component of the anti-tumor effects mediated by TTP transgene induction ([Figure 7](#fig7){ref-type="fig"}C). As expected, CT26 cells expressing a *Cd274* cDNA with the full-length, wild-type 3′ UTR (PD-L1 WT 3′ UTR) had considerably lower expression of PD-L1 protein than the PD-L1 Δ3′ UTR cells, but still responded to TTP induction in terms of reductions in PD-L1 expression ([Figure S7](#mmc1){ref-type="supplementary-material"}F) and control of tumor growth in immune-competent mice ([Figure S7](#mmc1){ref-type="supplementary-material"}G).

Consistent with a heightened anti-tumor immune response, tumors derived from mice treated with doxycycline had a greater degree of CD3^+^ lymphocyte infiltration than tumors from mice treated with vehicle, and this corresponding infiltration was abrogated in tumors derived from cells overexpressing PD-L1 Δ3′ UTR ([Figures 7](#fig7){ref-type="fig"}G and [S7](#mmc1){ref-type="supplementary-material"}H). Moreover, we found higher CD8^+^/Treg cell ratios in tumors expressing the TTP transgene and higher levels of IFN-γ production by CD8^+^ tumor-infiltrating lymphocytes (TILs) derived from TTP-expressing tumors, versus PD-L1 Δ3′ UTR tumors expressing TTP ([Figure 7](#fig7){ref-type="fig"}H); however, we did not find significant differences in CD4^+^ TIL populations (data not shown).

Collectively, these data highlight the functional importance of the regulation of PD-L1 expression by TTP in tumor progression and demonstrate that this novel regulatory pathway may be exploited for the treatment of *Ras* mutant cancers. These findings support a model whereby tumor-specific suppression of TTP can foster PD-L1 upregulation, and ultimately, tumor immunoresistance ([Figures 7](#fig7){ref-type="fig"}I and [S7](#mmc1){ref-type="supplementary-material"}I).

Discussion {#sec3}
==========

In this report, we demonstrate that oncogenic RAS signaling can increase tumor cell-intrinsic PD-L1 expression, implying that mutant RAS oncogenes can directly contribute to the evasion of immune destruction in cancer. We revealed that RAS-MEK signaling controlled expression of PD-L1, at least in part, by modulating the stability of the transcript. We showed that the mouse and human PD-L1 mRNAs were labile transcripts containing functional AU-rich elements (AREs) in the 3′ UTR that permitted regulation of PD-L1 expression by RAS. Our data provide a potential explanation for the genomic structural variations in the *CD274* 3′ UTR observed in human cancer ([@bib26]). The simultaneous loss of regulation by miRNAs and AREs is likely to contribute to the high overexpression observed in tumors with complete loss of the 3′ UTR. In addition, we provide a molecular basis for the tendency of *KRAS* mutant NSCLCs to be positive for PD-L1 expression ([@bib10], [@bib13], [@bib31], [@bib57]), implying that PD-1-PD-L1 blockade may prove more successful in *RAS* mutant patients that also harbor a sufficient number of tumor antigens.

We identify TTP as a principle AU-rich element binding protein responsible for negatively regulating PD-L1 expression, consistent with a previous report identifying PD-L1 mRNA as one of a number of TTP targets in an RNA immunoprecipitation, microarray-based screen in mouse macrophages ([@bib49]). Mechanistically, MEK inhibition reduced PD-L1 mRNA stability, coinciding with an increase in TTP expression and reduction in phosphorylation of TTP at ERK and RSK/AKT consensus motifs. Conversely, activation of RAS and the associated ROS accumulation led to enhanced TTP phosphorylation, notably by MK2 at key inhibitory sites.

TTP transgene expression restrained tumor growth in CT26 and MC38 tumor transplantation models. This anti-tumor effect is predominantly non-cell autonomous, dependent on the adaptive immune system and suppression of tumor cell PD-L1 expression. We noted only minor reductions in tumor growth rates following TTP transgene induction in cells overexpressing PD-L1 Δ3′ UTR. TTP has been reported to have cell-autonomous tumor-suppressive roles ([@bib45]) and non-cell-autonomous anti-tumor effects through targeting VEGF and COX-2 mRNAs ([@bib8], [@bib17]), which may contribute to some of these ostensibly PD-L1-independent effects, the magnitude of which are likely to be determined by the level of TTP overexpression in each system.

Our data extend the molecular understanding of the regulation of PD-L1 expression in cancer and highlight druggable targets to enhance anti-tumor immunity in tumors that are wild-type for the *CD274* 3′ UTR. We provide evidence that pharmacological targeting of RAS, or RAS effector proteins, may elicit non-cell-autonomous anti-tumor effects in *RAS* mutant tumors. Recently, MEK inhibitors and PD-1 pathway blockade were shown to combine strongly in a mouse model of *Ras* mutant colon carcinoma ([@bib15], [@bib34]). We anticipate that our findings will inform the development of effective combination therapies with immune checkpoint blockade in cancer.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**p-ERKCell Signaling TechnologyCat\# 9101p-AKT (S473)Cell Signaling TechnologyCat\# 9271PD-L1 (anti-human)eBioscienceCat\# 12-5983-42Isotype controleBioscienceCat\# 9012-4714-025PD-L1 (anti-mouse)eBioscienceCat\# 14-5982-82Isotype controleBioscienceCat\# 12-4321-41CD31eBioscienceCat\# 11-0311-81TTPSanta CruzCat\# sc-8458TTP endogenousMerck MilliporeCat\# ABE285KSRPCambridge BioscienceCat\# A302-021AKSRPCell Signaling TechnologyCat\# 5398SMyc (9E10)Francis Crick Institute Cell ServicesN/AERKCell Signaling TechnologyCat\# 9107AKTCell Signaling TechnologyCat\# 2920p-PXSPCell Signaling TechnologyCat\# 2325p-RXXS/TCell Signaling TechnologyCat\# 9611p-p38 (T180/Y182)Cell Signaling TechnologyCat\# 9211CD3AbcamCat\# ab134096IFN-γ XMG1.2eBioscienceCat\# 12-7311-41Foxp3 FJK16seBioscienceCat\# 72-5775-40CD45 30-F11BioLegendCat\# 103129CD4 GK1.5Francis Crick Institute Cell ServicesN/ACD4 GK1.5eBioscienceCat\# 25-0041-81CD4 RM4-5eBioscienceCat\# 11-0042-81CD8 53-6.7BD BiosciencesCat\# 563786CD8 2.43Francis Crick Institute Cell ServicesN/ACD3 17A2BioLegendCat\# 100204CD45eBioscienceCat\# 11-0451-82IFN-γ NIB42eBioscienceCat\# 14-7318-81**Bacterial and Virus Strains**Adenovirus for expression of Cre recombinaseGene Transfer Vector Core. University of Iowa.N/AXL10-Gold Ultracompetent CellsAgilent TechnologiesCat\# 200314**Chemicals, Peptides, and Recombinant Proteins**Lipofectamine 2000ThermoFisherCat\# 11668027DharmaFECT 1DharmaconCat\# T-2001-01TrametinibSelleckchemCat\# S2673ARS853A gift from the Shokat LaboratoryN/AGDC-0941SelleckchemCat\# S10654-OHTSigma-AldrichCat\# H7904PMASigma-AldrichCat\# P1585Actinomycin DSigma-AldrichCat\# A1410N-Acetyl-L-cysteineSigma-AldrichCat\# A9165Glutathione reduced ethyl esterSigma-AldrichCat\# G1404PF-3644022 hydrateSigma-AldrichCat\# PZ0188MK2 inhibitor IIIMerck MilliporeCat\# 475864Doxycycline hyclateSigma-AldrichCat\# D9891IonomycinSigma-AldrichCat\# I0634GolgiPlugBD BioscienceCat\# BDB555029Human Interferon gammaBiolegendCat\# 570206RuxolitinibSelleckchemCat\# S1378DAPIThermoFisherCat\# D1306Fixable viability dye eFluor 780eBioscienceCat\# 65-0865-14H~2~DCFDAThermoFisherCat\# C6827**Critical Commercial Assays**Dual-Luciferase Reporter AssayPromegaCat\# E1910Magna-RIP KitMerck MilliporeCat\# 17-700Anti-Mouse/Rat Foxp3 Staining Set PEeBioscienceCat\# 72-5775-40QuikChange II XL Site-Directed Mutagenesis KitAgilent TechnologiesCat\# 200521RNeasy Mini KitQIAGENCat\# 74104Dynabeads Protein G for ImmunoprecipitationThermoFisherCat\# 10003DSYBR Green Fast Master MixThermoFisherCat\# A25742**Experimental Models: Cell Lines**H358ATCCN/AA427Francis Crick Institute Cell ServicesN/AH1792ATCCN/AKPB6Sergio Quezada LaboratoryN/AType II pneumocytesOlivier Pardo, Michael Seckl (Imperial College, London) and ([@bib38])N/ASW837Francis Crick Institute Cell ServicesN/AH23Francis Crick Institute Cell ServicesN/A293FTFrancis Crick Institute Cell ServicesN/ATTP KO and TTP WT MEFsPerry Blackshear LaboratoryN/AMCF10A[@bib38]N/ACT26Francis Crick Institute Cell ServicesN/AA549Francis Crick Institute Cell ServicesN/AMC38George Kassiotis LaboratoryN/A**Experimental Models: Organisms/Strains**C57BL/6The Francis Crick Institute Biological Resources Unit; Originally The Jackson LaboratoryStock Number \#000664BALB/cThe Francis Crick Institute Biological Resources Unit; Originally The Jackson LaboratoryStock Number \#001026*Kras*^*LSL-G12D/+*^*/Trp53*^*Flox/Flox*^ (B6.129-*Kras*^*tm4Tyj*^/Nci and FVB.129P2-*Trp53*^*tm1Brn*^/Nci)The Francis Crick Institute Biological Resources Unit; Originally Mouse Models of Human Cancer ConsortiumStrain Number\# 01XJ6; 01XC2*Nu/nu* (Foxn1^nu^)The Francis Crick Institute Biological Resources Unit; Originally ICRF StockN/A**Oligonucleotides**siGENOME x4 TTPDharmaconCat\# MU-010789-02-0002siGENOME x4 AUF1DharmaconCat\# MU-004079-01-0002siGENOME x4 KSRPDharmaconCat\# MU-009490-01-0002siGENOME x4 HuRDharmaconCat\# MU-003773-04-0002siGENOME x4 BRF1DharmaconCat\# MU-011816-00-0002siGENOME x4 BRF2DharmaconCat\# MU-013605-02-0002siScramble ControlDharmaconCat\# D-001810-10-05**Recombinant DNA**peGFPC1-6XHis-FL-KSRPA gift from Douglas BlackAddgene plasmid \# 23001PD-L1 + wild type 3′UTR mouse ORF clone NM_021893.3Creative BiogeneN/ApUNO-mcsInvivoGenCat\# puno1-mcspTRIPZDharmaconCat\# RHS4740pcDNA3.1ThermoFisherCat\# V79020pGL3 ControlPromegaCat\# E1741pGL3 BasicPromegaCat\# E1751pRL-TK ControlPromegaCat\# E2241**Software and Algorithms**FlowJoTree StarN/APrism 7GraphPadN/ASkyline v.3.5.0.9319McCoss Lab SoftwareN/A
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Julian Downward (<julian.downward@crick.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell Lines {#sec4.3.1}

Specific culture conditions and origin of all the cell lines used in this study are listed in the [Key Resources Table](#sec4.1){ref-type="sec"} and [Table S2](#mmc1){ref-type="supplementary-material"}. Cell lines were authenticated by STR profiling by Cell Services at the Francis Crick Institute. Cells and antibodies used for *in vivo* studies were independently tested for common rodent pathogens and were certified as pathogen-free.

### *In vivo* studies {#sec4.3.2}

All studies were performed under a UK Home Office approved project license and in accordance with institutional welfare guidelines. For tumor studies, we used 8-10 week old BALB/c or *nu/nu* (*Foxn1*^*nu*^) mice (for CT26 cells) or 16-17 week old C57BL/6 mice (for MC38 cells). Sex-matched mice were randomly assigned into experimental groups before tumor cell injection. Group sizes are indicated in the figure legends.

For autochthonous tumor formation, *Kras*^*LSL-G12D/+*^; *Trp53*^*F/F*^ mice were sourced from the Mouse Models of Human Cancer Consortium (B6.129-*Kras*^*tm4Tyj*^/Nci and FVB.129P2-*Trp53*^*tm1Brn*^/Nci) and were backcrossed to C57BL/6 for 6 generations. Lung tumors were initiated using intratracheal intubation of 1x10^6^ pfu adenovirus expressing Cre-recombinase (Gene Transfer Vector Core) in mice between 6-12 weeks of age. Lung tumor or normal lung tissue was analyzed 12 weeks after infection.

Method Details {#sec4.4}
--------------

### *In vivo* studies {#sec4.4.1}

Mice received 1x10^5^ cells in PBS by subcutaneous injection into the left flank. Mice were treated with water or doxycycline by oral gavage (50 mg/kg) on day three after cell injection and then daily, with a two-day break every five days of treatment. For CD4^+^ and CD8^+^ cell depletion experiments, mice received 300 μg of GK1.5 and 300 μg of 2.43 monoclonal antibodies or rat IgG2b isotype control by i.p. administration three days before tumor cell engraftment and then twice weekly for the duration of the experiment. Depletion of CD8^+^ and CD4^+^ T cells was verified by flow cytometry using detection antibodies recognizing distinct epitopes from the depletion antibodies. Tumors were measured using callipers and volume was estimated using the formula: width^2^ x length x 0.5, where length is the longest dimension and width is the corresponding perpendicular dimension.

### Transfections {#sec4.4.2}

For RNA interference, cells were reverse-transfected with a final concentration of 50 nM siGENOME siRNA pools or ON-TARGETplus Non-targeting pool ("SiScrambled" control) or 25 nM for single deconvoluted siRNAs, and DharmaFECT 1 transfection reagent (Dharmacon; GE Healthcare) in 96 well plates. For transfection with TTP or KSRP constructs, cells were seeded in a 12 well plate and the following day transfected using Lipofectamine 2000 (Life Technologies).

### Cloning, plasmids and stable cell lines {#sec4.4.3}

peGFPC1-6XHis-FL-KSRP was a gift from Douglas Black (Addgene plasmid \# 23001)([@bib22]) and the S193A mutant was generated by site-directed mutagenesis (QuikChange II; Agilent Technologies). Full length human TTP was cloned from H358 genomic DNA into pcDNA3-MycX2 generating two N-terminal Myc tags. The S218 S228A TTP human and S52A S178A mouse double mutant constructs were generated by site-directed mutagenesis (QuikChange II; Agilent Technologies).

For the human PD-L1 (*CD274* gene) we refer to GRCh38:CM000671.2. For human PD-L1 mRNA we refer to NM_014143. For mouse PD-L1 (*Cd274* gene) we refer to GRCm38:CM001012.2. For mouse PD-L1 mRNA we refer to NM_021893. For the 3′UTR luciferase reporter constructs, the full length human *CD274* 3′UTR was cloned from H358 genomic DNA into the TOPO-TA vector (Life Technologies). The six most 3′ ATTTA pentamers (including the three most highly conserved, as shown in [Figure 2](#fig2){ref-type="fig"}D) were mutated to ATGTA (QuikChange Multi-site; Agilent). Wild-type and mutant fragments were subcloned into the Xba1, BamH1 site of pGL3-Control (Promega) to generate the reporter constructs.

CT26 cells were transfected with linearized pUNO empty and pUNO-mouse *Cd274* Δ3′UTR plasmids (InvivoGen) before selection with blasticidin, and for *Cd274* Δ3′UTR cells ('PD-L1 Δ3′UTR'), subsequent FACS sorting of PD-L1 high, blasticidin-resistant cells. PD-L1 with the wild-type 3′UTR was subcloned from pcDNA3.1 mouse ORF clone NM_021893.3 (Creative Biogene) into the pUNO vector, linearized and transfected into CT26 cells to generate a stable cell line following selection with blasticidin and sorting for PD-L1 high cells.

For the lentiviral pTRIPZ constructs, full-length mouse TTP (*Zfp36*) was cloned from KPB6 genomic DNA into pcDNA3-MycX2 generating two N-terminal Myc tags. MycX2-TTP was subsequently subcloned into the Age1-Mlu1 site of pTRIPZ-empty (GE Healthcare), resulting in the final TTP (tet-ON) construct, without the TurboRFP or shRNAmir-related elements of the parental pTRIPZ plasmid. Lentiviral particles were produced by co-transfection of 293FT cells with pTRIPZ-TTP, psPAX2 and pMD2.G plasmids and the infected CT26 or MC38 target cells were selected with puromycin to establish stable cell lines.

For *CD274* promoter reporter constructs, pGL3-Basic (Promega) served as a negative control and pGL3-Control (Promega) served as a positive control for firefly luciferase expression. The indicated fragments of the human *CD274* promoter region were cloned from H358 genomic DNA into the MluI -- XhoI site of pGL3-Basic. In addition, the putative enhancer site in intron 1 of the human *CD274* gene was cloned into the BamH1 -- SalI site (downstream of the firefly luciferase ORF) of the 1 kb *CD274* promoter pGL3-Basic reporter construct, as shown in [Figure S2](#mmc1){ref-type="supplementary-material"}A. Sequencing of these constructs and comparison to the GRCh38 assembly revealed two documented SNPs in the putative enhancer region fragment: rs4742097 and rs2282055.

### Flow cytometry {#sec4.4.4}

Lung tissue was harvested in ice-cold PBS before mincing and then enzymatic digestion in Liberase TM and Liberase TH (both 75 μg/ml final; Roche) or collagenase I (1 mg/ml) with DNaseI (25 μg/ml final; Sigma) in HBSS (GIBCO) for 45 min at 37°C. After washing in DMEM + 10% FCS, cells were filtered through 70 μm filters (BD Bioscience) and then washed in FACS buffer (PBS supplemented with 2 mM EDTA and 0.5% BSA v/v final). Samples were then treated with Red Blood Cell Lysis Buffer (QIAGEN), washed in FACS buffer, filtered again and resuspended with FcR blocking reagent (BD Bioscience) before antibody staining of cell surface antigens in FACS buffer. For unfixed cells, samples were washed twice in FACS buffer and resuspended in DAPI (1 μg/ml final; eBioscience) immediately before analysis on LSRII or LSRFortessa (BD Biosciences) cell analysers. Intracellular staining for Foxp3 and IFN-γ was performed on fixed cells using the Foxp3 Staining Set (eBiosicence) according to manufacturer's instructions. CD4^+^ Tregs were defined by Foxp3 positivity. For IFN-γ staining, cells were stimulated for 4 h *ex-vivo* with PMA (20 ng/ml) and ionomycin (1 μg/ml) in the presence of GolgiPlug (BD Biosciences). Dead cells were excluded using the fixable viability dye eFluor 780 (eBioscience).

For FACS analysis of cell lines, cells were harvested with trypsin, washed in media and filtered before antibody staining in FACS buffer. Samples were washed twice in FACS buffer and resuspended in DAPI (1 μg/ml final; eBioscience) immediately before analysis. For the detection of intracellular ROS, adherent cells were washed in PBS before staining in 5 μM H~2~DCFDA for 20 min in PBS at 37°C. Cells were then harvested by trypsinisation and prepared for flow cytometry as described above.

### Immunoprecipitation {#sec4.4.5}

For each immunoprecipitation reaction, 25 μl slurry of Dynabeads (Life Technologies) were coupled with 3 μg of anti-Myc antibody (9E10; in-house) or normal mouse IgG. For [Figure 5](#fig5){ref-type="fig"}H, cross-linking was performed using DSS following manufacturer's instructions (ThermoFisher). Beads were washed in Lysis Buffer (20 mM Tris-HCl, pH 7.4, 137.5 mM NaCl, 10% glycerol, 1% Triton X-100) and incubated overnight with rotation at 4°C with cleared cell lysates prepared in Lysis Buffer supplemented with protease and phosphatase inhibitor cocktails (Calbiochem). Beads were washed three times with IP Wash Buffer (modified Lysis Buffer: 0.1% Triton X-100, final), before elution with LDS Sample Buffer (Life Technologies).

### Immunohistochemistry {#sec4.4.6}

Tissue was prepared for histology by incubation in 10% NBF for 24 h followed by 70% ethanol for a further 24 h before embedding in paraffin. For CD3 staining, sections were boiled in sodium citrate buffer (pH6) for 15 min and incubated for 1 h in anti-CD3 antibody (ab134096; Abcam), followed by biotinylated secondary antibody and HRP/DAB detection. Tumors from *nu/nu* mice served as a negative control for CD3 staining. Hematoxylin and eosin staining was performed using standard methods.

### CRISPR/Cas {#sec4.4.7}

The CRISPR/Cas genome editing was performed on CT26 cells using a U6gRNA-Cas9-2A-GFP construct targeting mouse *Zfp36* with a gRNA sequence GTCATGGCTCATCGACTGGAGG (Sigma, MM0000323992). Following plasmid transfection, single GFP-positive cells were selected by FACS for expansion in culture. Transfection with Cas9-2A-GFP alone served as a negative control. KO of functional TTP was confirmed by western blotting and complete *Zfp36* allele disruption was confirmed by TOPO-TA cloning followed by sequencing.

### Bioinformatics {#sec4.4.8}

Using two published RAS activation gene expression signatures ([@bib35], [@bib52]), we identified high and low RAS pathway activity LUAD TCGA RNASeq samples. We determined high and low RAS pathway activity using GSEA (GeneSetTest, Bioconductor) against genes ranked by their log2 normalized counts scaled across all tumor samples. Only the upregulated genes from the signatures were used in the GSEA. Samples with a significant GSEA association (FDR \< 0.05) of a RAS signature to the upper portion of the rank were assigned as having high RAS activity. Those with a significant association to the lower portion of the rank were assigned as having low RAS activity. Once assigned, we identified RAS-dependent gene expression changes between the high and low RAS activity groups by standard RNASeq analysis methods (DESeq2, FDR \< 0.05). A short-list of "T cell Function" related genes was generated from gene ontology annotation based on the nanoString Technologies nCounter Human PanCancer Immune Profiling Panel.

### Mass Spectrometry {#sec4.4.9}

Gel bands were excised and subjected to digestion with trypsin. Tryptic peptides were analyzed by LC-MS using Ultimate 3000 uHPLC system connected to a Q-Exactive mass spectrometer (Thermo Fisher Scientific) and acquired in data-dependent mode (DDA) for identification and in targeted SIM/PRM mode for quantification. A SIM isolation list was setup for the following peptides: STSLVEGR (m/z 424.7272, 2+, non phos), STSLVEGR (m/z 464.7104, 2+, phos S52), QSISFSGLPSGR (m/z 618.3276, 2+, non phos) and QSISFSGLPSGR (m/z 658.3057, 2+, phos S178). For SIM/PRM scans, MS1 peaks were acquired at resolution of 70,000 (at m/z 200) and scan time (1x256 ms); MS2 fragment ion resolution was 17,500 (at m/z 200) scan time (64x4 ms); and SIM/PRM cycle time was (1280 ms). For identification and generation of spectral libraries, the resulting DDA data was searched against a mouse Uniprot database containing common contaminants (UniProt_KB2012_08_taxonomy_mouse_10090_canonical_with_contaminants.fasta) as well as a custom database containing the Myc-tagged mouse Zfp36 sequence using the Andromeda search engine and MaxQuant (version 1.3.0.5). For MaxQuant, a false discovery rate of 0.1% was used to generate protein, peptide and site identification tables. The targeted mass spectrometry raw data was uploaded into Skyline (version 3.5.0.9319) for identification, quantification and further statistical analyses.

### Western blotting {#sec4.4.10}

Western blotting was performed using standard methods. Primary antibodies used are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}. Secondary antibodies were conjugated to horseradish peroxidase (GE Healthcare).

### Luciferase assays {#sec4.4.11}

H358, ER-HRAS^G12V^ MCF10A and KP (tetON) cells were plated in 96 well plates and the following day co-transfected with pRL-TK control and pGL3-3′UTR PD-L1 luciferase constructs using Lipofectamine 2000 (Life Technologies). 24 h after transfection, PMA (200 nM; Sigma), doxycycline (1 μg/ml; Sigma) or MEK inhibitor GSK1120212 (25 nM; Selleckchem) was added, and 6-7 h later the Dual-Luciferase Reporter Assay (Promega) was performed. For ER-HRAS^G12V^ MCF10A, 24 h after transfection cells were serum-starved overnight, and then treated with 4-OHT (100 nM) for 24 h before the Dual-Luciferase Reporter Assay (Promega) was performed.

### Quantitative real-time PCR (qPCR) {#sec4.4.12}

RNA was extracted using RNeasy Mini Kit (QIAGEN), cDNA was generated using SuperScript VILO or SuperScript II Reverse Transcriptase (Life Technologies) and qPCR reactions were carried out using QuantiTect Primer Assays (QIAGEN) and SYBR Green reagents (Life Technologies). Gene expression changes relative to the stated housekeeping gene were calculated using the ΔΔCT method.

### RNA-immunoprecipitation {#sec4.4.13}

RNA-immunoprecipitation (RNA-IP) reactions were carried out using Magna-RIP RNA-IP Kit (Millipore) with IgG control, anti-TTP or anti-KSRP antibodies according to the manufacturer's instructions, except for the exclusion of EDTA from lysis and wash buffers, as TTP is a zinc-finger protein. Total RNA was isolated and qPCR was carried out using methods specified in the above section, except using the % input method to calculate RNA enrichment.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical tests, *p*-values, replicates and the definition of center and dispersion are indicated in the figures and figure legends. Unless otherwise stated in the figure legend, we used an unpaired, two-tailed Student's t test, where statistical significance was defined by p \< 0.05. Statistical analyses were carried out in GraphPad Prism 7.
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